corilagin has been researched along with Atherogenesis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Chen, P; He, B; Shen, Z; Yang, R; Yang, Y; Zhang, X | 1 |
| Chen, P; He, B; Hu, Q; Jin, H; Shen, Z; Tao, Y; Yang, R; Yang, Y; Zhang, L; Zhang, X | 1 |
2 other study(ies) available for corilagin and Atherogenesis
| Article | Year |
|---|---|
Antiatherosclerotic effects of corilagin via suppression of the LOX-1/MyD88/NF-κB signaling pathway in vivo and in vitro.
Topics: Animals; Atherosclerosis; Glucosides; Hydrolyzable Tannins; Myeloid Differentiation Factor 88; NF-kappa B; Rabbits; Scavenger Receptors, Class E; Signal Transduction | 2022 |
Corilagin ameliorates atherosclerosis by regulating MMP-1, -2, and -9 expression in vitro and in vivo.
Topics: Animals; Atherosclerosis; Carotid Artery, Common; Diet, High-Fat; Disease Models, Animal; Glucosides; Humans; Hydrolyzable Tannins; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; RAW 264.7 Cells; Swine; Swine, Miniature | 2021 |